News
References Reference: Press release on the orphan drug designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA (May 7, 2025).
MEDIPAL HOLDINGS CORPORATION(TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd.(TSE 4552, JCR) today announced that the European Commission (EC) has granted orphan drug designation (ODD) to JR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback